Alongside its first-quarter financials today, Pfizer also sneaked in details of its “discontinued projects,” this year, which includes meds from its CV and metabolism pipeline and from its neuroscience unit.
The ax swung in the last few months for PF-06291874, a midstage med in testing for Type 2 diabetes; PF-06815345 for hyperlipidemia; and PF-06412562 for cognitive disorders, and PF-02545920, a PDE10 inhibitor in phase 2 for Huntington's disease saw the chop in the first quarter.
Its diabetes med was a glucagon receptor antagonist, while its hyperlipidemia candidate was, according to its FY update last February, new in to its pipeline for phase 1 testing, but with precious few other details about its MOA. The same goes for PF-06412562, also a phase 1 candidate, in its neuroscience and pain unit.
The phase 2 Huntington's disease candidate, out of its neuroscience department, was a small molecule NME that had orphan status in the U.S. According to clinicaltrials.gov, the: "Study terminated on 15 Dec. 2016 due to study A8241021 showing no significant difference on primary endpoint between PF-02545920 & placebo. No safety concerns."
In its financials, Pfizer also revealed that it spent $1.7 billion in R&D in the first quarter, a 1% decline on last year.